Issue Date: February 6, 2012
Sangamo And Shire To Tackle Hemophilia
Sangamo BioSciences and Ireland’s Shire are collaborating on curative therapies for hemophilia and other monogenic diseases. They will use Sangamo’s zinc finger DNA-binding protein (ZFP) technology for gene editing. To get exclusive worldwide rights to ZFPs targeting four genes—for blood clotting factors VII, VIII, IX, and X—Shire will pay Sangamo $13 million up front, as well as future milestones and royalties. Sangamo will handle R&D up to the clinical-trial stage, with Shire reimbursing its expenses.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society